全文获取类型
收费全文 | 5673篇 |
免费 | 417篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 206篇 |
妇产科学 | 237篇 |
基础医学 | 710篇 |
口腔科学 | 52篇 |
临床医学 | 936篇 |
内科学 | 996篇 |
皮肤病学 | 333篇 |
神经病学 | 503篇 |
特种医学 | 141篇 |
外科学 | 335篇 |
综合类 | 46篇 |
一般理论 | 4篇 |
预防医学 | 865篇 |
眼科学 | 25篇 |
药学 | 362篇 |
中国医学 | 6篇 |
肿瘤学 | 308篇 |
出版年
2023年 | 45篇 |
2022年 | 43篇 |
2021年 | 114篇 |
2020年 | 70篇 |
2019年 | 112篇 |
2018年 | 135篇 |
2017年 | 112篇 |
2016年 | 128篇 |
2015年 | 141篇 |
2014年 | 188篇 |
2013年 | 289篇 |
2012年 | 389篇 |
2011年 | 412篇 |
2010年 | 193篇 |
2009年 | 171篇 |
2008年 | 384篇 |
2007年 | 373篇 |
2006年 | 410篇 |
2005年 | 422篇 |
2004年 | 407篇 |
2003年 | 364篇 |
2002年 | 335篇 |
2001年 | 57篇 |
2000年 | 37篇 |
1999年 | 57篇 |
1998年 | 71篇 |
1997年 | 61篇 |
1996年 | 53篇 |
1995年 | 52篇 |
1994年 | 33篇 |
1993年 | 34篇 |
1992年 | 28篇 |
1991年 | 22篇 |
1990年 | 28篇 |
1989年 | 25篇 |
1988年 | 18篇 |
1987年 | 19篇 |
1986年 | 17篇 |
1985年 | 21篇 |
1984年 | 27篇 |
1983年 | 11篇 |
1982年 | 22篇 |
1981年 | 29篇 |
1980年 | 26篇 |
1979年 | 16篇 |
1978年 | 17篇 |
1976年 | 10篇 |
1975年 | 10篇 |
1974年 | 13篇 |
1973年 | 9篇 |
排序方式: 共有6095条查询结果,搜索用时 15 毫秒
971.
972.
Salha FendriDominique Rose Sonia MyambuSandrine Jeanne Jean-Daniel Lalau 《Diabetes research and clinical practice》2011,91(1):e21
We assessed glycaemic status in 26 overweight or obese people with type 2 diabetes suspected of having sleep apnoea syndrome (SAS). In people with SAS (n = 13), nocturnal glycaemia was 38% higher, independent of body mass index (particularly during rapid eye movement sleep) compared with non-SAS subjects (p < 0.008). 相似文献
973.
Fendri S Rose D Myambu S Jeanne S Lalau JD 《Diabetes research and clinical practice》2011,94(1):e21-e23
The prevalence of Gestational Diabetes Mellitus (GDM) diagnosed by WHO criterion (2-hPG ≥ 7.8 mmol/L) was 13.4%. By International Association of Diabetes and Pregnancy Study Groups criteria of FPG ≥ 5.1 mmol/L, prevalence of GDM was 3.2%. FPG may not be suitable for diagnosis of GDM in Asian Indians due to high insulin resistance in addition to pregnancy hormonal effect. 相似文献
974.
Gerber JM Qin L Kowalski J Smith BD Griffin CA Vala MS Collector MI Perkins B Zahurak M Matsui W Gocke CD Sharkis SJ Levitsky HI Jones RJ 《American journal of hematology》2011,86(1):31-37
Although tyrosine kinase inhibitors have redefined the care of chronic myeloid leukemia (CML), these agents have not proved curative, likely due to resistance of the leukemia stem cells (LSC). While a number of potential therapeutic targets have emerged in CML, their expression in the LSC remains largely unknown. We therefore isolated subsets of CD34(+) stem/progenitor cells from normal donors and from patients with chronic phase or blast crisis CML. These cell subsets were then characterized based on ability to engraft immunodeficient mice and expression of candidate therapeutic targets. The CD34(+)CD38(-) CML cell population with high aldehyde dehydrogenase (ALDH) activity was the most enriched for immunodeficient mouse engrafting capacity. The putative targets: PROTEINASE 3, SURVIVIN, and hTERT were expressed only at relatively low levels by the CD34(+)CD38(-)ALDH(high) CML cells, similar to the normal CD34(+)CD38(-)ALDH(high) cells and less than in the total CML CD34(+) cells. In fact, the highest expression of these antigens was in normal, unfractionated CD34(+) cells. In contrast, PRAME and WT1 were more highly expressed by all CML CD34(+) subsets than their normal counterparts. Thus, ALDH activity appears to enrich for CML stem cells, which display an expression profile that is distinct from normal stem/progenitor cells and even the CML progenitors. Indeed, expression of a putative target by the total CD34(+) population in CML does not guarantee expression by the LSC. These expression patterns suggest that PROTEINASE 3, SURVIVIN, and hTERT are not optimal therapeutic targets in CML stem cells; whereas PRAME and WT1 seem promising. 相似文献
975.
976.
Hernaez R Lazo M Bonekamp S Kamel I Brancati FL Guallar E Clark JM 《Hepatology (Baltimore, Md.)》2011,54(3):1082-1090
Ultrasonography is a widely accessible imaging technique for the detection of fatty liver, but the reported accuracy and reliability have been inconsistent across studies. We aimed to perform a systematic review and meta-analysis of the diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver. We used MEDLINE and Embase from October 1967 to March 2010. Studies that provided cross-tabulations of ultrasonography versus histology or standard imaging techniques, or that provided reliability data for ultrasonography, were included. Study variables were independently abstracted by three reviewers and double checked by one reviewer. Forty-nine (4720 participants) studies were included for the meta-analysis of diagnostic accuracy. The overall sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of ultrasound for the detection of moderate-severe fatty liver, compared to histology (gold standard), were 84.8% (95% confidence interval: 79.5-88.9), 93.6% (87.2-97.0), 13.3 (6.4-27.6), and 0.16 (0.12-0.22), respectively. The area under the summary receiving operating characteristics curve was 0.93 (0.91-0.95). Reliability of ultrasound for the detection of fatty liver showed kappa statistics ranging from 0.54 to 0.92 for intrarater reliability and from 0.44 to 1.00 for interrater reliability. Sensitivity and specificity of ultrasound was similar to that of other imaging techniques (i.e., computed tomography or magnetic resonance imaging). Statistical heterogeneity was present even after stratification for multiple clinically relevant characteristics. Conclusion: Ultrasonography allows for reliable and accurate detection of moderate-severe fatty liver, compared to histology. Because of its low cost, safety, and accessibility, ultrasound is likely the imaging technique of choice for screening for fatty liver in clinical and population settings. 相似文献
977.
Hassenstab JJ Sweet LH Del Parigi A McCaffery JM Haley AP Demos KE Cohen RA Wing RR 《Psychiatry research》2012,202(1):77-79
Cortical thickness of the cognitive control network was contrasted between obese (OB), successful weight loss maintainers (SWLM), and lean individuals. OB individuals had significant thinning, most notably in the anterior cingulate and posterior parietal cortices. SWLM individuals exhibited trends towards thicker cortex than OB individuals, which may be important in future studies. 相似文献
978.
Salazar DE Mendell J Kastrissios H Green M Carrothers TJ Song S Patel I Bocanegra TS Antman EM Giugliano RP Kunitada S Dornseif B Shi M Tachibana M Zhou S Rohatagi S 《Thrombosis and haemostasis》2012,107(5):925-936
Edoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The objectives of the present analyses were to characterise edoxaban population pharmacokinetics (PPK) and identify potential intrinsic and extrinsic factors affecting variability in edoxaban exposure, determine if there are relationships between edoxaban pharmacokinetics or biomarkers and the risk of bleeding in patients with NVAF using an exposure-response model, and to use the PPK and exposure-response model to support dose selection for a phase III trial of edoxaban in patients with NVAF. PPK analysis of data from 1,281 edoxaban-dosed subjects with intrinsic factors such as renal impairment or NVAF and extrinsic factors such as concomitant medications revealed significant effects of renal impairment and concomitant strong P-glycoprotein (P-gp) inhibitors on the pharmacokinetics of edoxaban. Exposure-response analysis found that in patients with NVAF, the incidence of bleeding events increased significantly with increasing edoxaban exposure, with steady-state minimum concentration (Cmin,ss) showing the strongest association. Clinical trial simulations of bleeding incidence were used to select 30 mg and 60 mg once-daily edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-gp inhibitors as the treatment regimens in the ENGAGE AF-TIMI 48 (NCT00781391) trial. 相似文献
979.
980.